Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints

Journal of Rheumatology

Volumn 28, Issue 12, 2001, Pages 2700-2704

  Bolognese, J A ^a   Ehrich, E W ^a   Schnitzer, T J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Composite measures; Effect sizes; Endpoint correlation; Endpoint precision; Osteoarthritis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANALGESICS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LACTONES; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; PLIABILITY; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME;

EID: 0035200553     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
2. Which outcome measures should be used in rheumatoid arthritis clinical trials?
3. Global statistical tests for comparing multiple outcomes in rheumatoid arthritis trials
4. Comparison of several composite endpoints in the assessment of MK-0966 efficacy in rheumatoid arthritis
5. Procedures for comparing samples with multiple endpoints
6. MK-966, a highly selective Cox-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study
7. MK-0966, a specific Cox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial
8. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis